查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1318004

NASH治疗及治疗药的全球市场(2023～2033年)

NASH Treatment & Therapeutics Market Report 2023-2033
出版日期: | 出版商: Visiongain | 英文 224 Pages | 商品交期: 最快1-2个工作天内

价格

全球NASH治疗及治疗药的市场规模到2033年前将以38.6％的年复合成长率成长。非酒精性脂肪性肝炎（NASH）患病率的增加、经济的快速增长、城市化和西化的生活方式正在推动市场的增长。

本报告提供全球NASH治疗及治疗药市场的相关调查，提供市场概要，市场分析，企业简介等全面性资讯。

目录

第1章 报告概要

第2章 摘要整理

第3章 市场概要

  • 主要调查结果
  • 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
  • COVID-19影响分析
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 竞争企业间的敌对关係
    • 替代品的威胁
    • 新加入厂商业者的威胁
  • PEST分析
  • 医药品开发平台(管线)的分析

第4章 NASH治疗及治疗药市场分析:各产品类型

  • 主要调查结果
  • NASH治疗及治疗药市场规模的估计及预测:各产品类型
  • 维生素E和?格列酮
  • 奥卡利瓦
  • 埃拉菲布拉诺
  • 塞伦塞蒂
  • 赛尼基韦罗
  • 其他

第5章 NASH治疗及治疗药市场分析:各用途

  • 主要调查结果
  • 用途市场区隔:市场魅力指数
  • NASH治疗及治疗药市场规模的估计及预测:各用途
  • 治疗
  • 诊断

第6章 NASH治疗及治疗药市场分析:各销售管道

  • 主要调查结果
  • 销售管道市场区隔:市场魅力指数
  • NASH治疗及治疗药市场规模的估计与预测:各销售管道
  • 医院药局
  • 线上供应商
  • 零售药局
  • 其他

第7章 NASH治疗及治疗药市场分析:各地区

  • 主要调查结果
  • 地区的市场规模的估计与预测

第8章 北美的NASH治疗及治疗药市场分析

第9章 欧洲的NASH治疗及治疗药市场分析

第10章 亚太地区的NASH治疗及治疗药市场分析

第11章 南美的NASH治疗及治疗药市场分析

第12章 中东及非洲的NASH治疗及治疗药市场分析

第13章 企业简介

  • 竞争情形(2022年)
  • 策略的展望
  • Intercept Pharmaceuticals, Inc.
  • Gilead Sciences Inc.
  • Genfit Pharma S.A.S
  • BioPredictive S.A.S
  • Galmed Pharmaceuticals Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Prometheus Laboratories Inc.
  • AbbVie Inc.
  • Enanta Pharmaceuticals Inc.
  • Genentech, Inc.

第14章 结论与推荐事项

  • 结论
  • 对市场参与企业的推荐事项
Product Code: PHA1271

The global NASH Treatment & Therapeutics market is projected to grow at a CAGR of 38.6% by 2033.

“The NASH Treatment & Therapeutics Market Report 2023-2033”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Prevalence of Non-alcoholic Steatohepatitis (NASH) Driving Market Growth

Some of the major forces propelling the NASH Treatment & Therapeutics market include increasing prevalence of NASH among the population, especially in developing countries. Moreover, Studies indicate a substantial rise in the incidence and prevalence of NASH, making it a significant public health issues, which is further expected to propel market growth. On the other hand, in developed countries such as the United States and Europe, NASH has emerged as the leading cause of chronic liver disease, surpassing hepatitis C. The prevalence of obesity, type 2 diabetes, and metabolic syndrome, all risk factors for NASH, has been steadily increasing, contributing to the rise in NASH cases. In addition, rapid urbanization, sedentary lifestyles, and changes in dietary patterns, including the consumption of high-calorie, processed foods, have further fuelled the epidemic and bolstered market growth.

Furthermore, NASH is not limited to developed nations but has also become a growing concern in developing countries. As these countries undergo rapid economic growth, urbanization, and the adoption of Westernized lifestyles, there has been a simultaneous increase in the prevalence of NASH.

Lack of Approved Therapies to Hamper Industry Growth

The lack of approved therapies for NASH has been a persistent challenge in recent years, leaving patients and healthcare providers with limited treatment options. However, there are currently no specific medications approved by regulatory authorities for the treatment of NASH. Clinical trials investigating potential treatments have faced significant challenges, with many failing to meet primary endpoints or demonstrating limited efficacy. Lack of standardization of the reading process across clinical drug development programs is one of the main reasons for failing trials. Promising drug candidates targeting various mechanisms involved in NASH pathogenesis, such as inflammation, fibrosis, and metabolic pathways, have not yet received regulatory approval due to a lack of compelling evidence from clinical studies.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the NASH Treatment & Therapeutics market evolving?
  • What is driving and restraining the NASH Treatment & Therapeutics market?
  • How will each NASH Treatment & Therapeutics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each NASH Treatment & Therapeutics submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading NASH Treatment & Therapeutics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the NASH Treatment & Therapeutics projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of NASH Treatment & Therapeutics projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the NASH Treatment & Therapeutics market?
  • Where is the NASH Treatment & Therapeutics market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the NASH Treatment & Therapeutics market today, and over the next 10 years:

  • Our 224-page report provides 78 tables and 111 charts/graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the NASH Treatment & Therapeutics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising NASH Treatment & Therapeutics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Product Type

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others

Application

  • Treatment
  • Diagnosis

Sales Channel

  • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the NASH Treatment & Therapeutics Market (Pipeline Analysis), 2023 to 2033, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • AbbVie Inc
  • BioPredictive S.A.S
  • Cadila Pharmaceuticals
  • Enanta
  • Galmed Pharmaceuticals
  • Genentech
  • Genfit
  • Gilead Sciences
  • Intercept Pharmaceuticals
  • Prometheus Laboratories

Overall world revenue for NASH Treatment & Therapeutics Market (Pipeline Analysis), 2023 to 2033 in terms of value the market will surpass US$4,650 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the NASH Treatment & Therapeutics Market (Pipeline Analysis), 2023 to 2033 report help you?

In summary, our 220+ page report provides you with the following knowledge:

  • Revenue forecasts to 2033 for NASH Treatment & Therapeutics Market (Pipeline Analysis), 2023 to 2033 Market, with forecasts for product type, application, sales channel, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 24 key national markets - See forecasts for the NASH Treatment & Therapeutics Market (Pipeline Analysis), 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the NASH Treatment & Therapeutics Market (Pipeline Analysis), 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the NASH Treatment & Therapeutics Market (Pipeline Analysis), 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to NASH Treatment & Therapeutics Market (Pipeline Analysis)
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Reports
  • 1.10 About

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Increasing Prevalence of NASH
      • 3.2.1.2 Growing Awareness and Diagnosis
      • 3.2.1.3 Increasing Healthcare Expenditure
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Lack of Approved Therapies
      • 3.2.2.2 Complex Disease Pathogenesis
      • 3.2.2.3 Clinical Trial Failures
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Technological Advancements
      • 3.2.3.2 Collaborations and Partnerships
      • 3.2.3.3 Diagnostic Tools and Biomarkers
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Bargaining Power of Suppliers
    • 3.4.2 Bargaining Power of Buyers
    • 3.4.3 Competitive Rivalry
    • 3.4.4 Threat from Substitutes
    • 3.4.5 Threat of New Entrants
  • 3.5 PEST Analysis
  • 3.6 Drug Pipeline Analysis

4 NASH Treatment & Therapeutics Market Analysis by Product Type

  • 4.1 Key Findings
  • 4.2 NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Product Type
  • 4.3 Vitamin E and Pioglitazone
  • 4.4 Ocaliva
  • 4.5 Elafibranor
  • 4.6 Selonsertib
  • 4.7 Cenicriviroc
  • 4.8 Others

5 NASH Treatment & Therapeutics Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Application
  • 5.4 Treatment
    • 5.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.4.2 Market Share by Region, 2023 & 2033 (%)
  • 5.5 Diagnosis
    • 5.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 5.5.2 Market Share by Region, 2023 & 2033 (%)

6 NASH Treatment & Therapeutics Market Analysis by Sales Channel

  • 6.1 Key Findings
  • 6.2 Sales Channel Segment: Market Attractiveness Index
  • 6.3 NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Sales Channel
  • 6.4 Hospital Pharmacy
    • 6.4.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.4.2 Market Share by Region, 2023 & 2033 (%)
  • 6.5 Online Provider
    • 6.5.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.5.2 Market Share by Region, 2023 & 2033 (%)
  • 6.6 Retail Pharmacy
    • 6.6.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.6.2 Market Share by Region, 2023 & 2033 (%)
  • 6.7 Others
    • 6.7.1 Market Size by Region, 2023-2033 (US$ Million)
    • 6.7.2 Market Share by Region, 2023 & 2033 (%)

7 NASH Treatment & Therapeutics Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America NASH Treatment & Therapeutics Market Analysis

  • 8.1 Key Findings
  • 8.2 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • 8.3 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) by Country, 2023, 2028 & 2033 (US$ Million)
  • 8.4 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Country
  • 8.5 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Application
  • 8.6 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Sales Channel
  • 8.7 U.S. NASH Treatment & Therapeutics Market Analysis
  • 8.8 Canada NASH Treatment & Therapeutics Market Analysis

9 Europe NASH Treatment & Therapeutics Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • 9.3 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) by Country, 2023, 2028 & 2033 (US$ Million)
  • 9.4 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Country
  • 9.5 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Application
  • 9.6 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Sales Channel
  • 9.7 Germany NASH Treatment & Therapeutics Market Analysis
  • 9.8 France NASH Treatment & Therapeutics Market Analysis
  • 9.9 UK NASH Treatment & Therapeutics Market Analysis
  • 9.10 Italy NASH Treatment & Therapeutics Market Analysis
  • 9.11 Spain NASH Treatment & Therapeutics Market Analysis
  • 9.12 Russia NASH Treatment & Therapeutics Market Analysis
  • 9.13 Rest of Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Analysis

10 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • 10.3 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) by Country, 2023, 2028 & 2033 (US$ Million)
  • 10.4 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Country
  • 10.5 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Application
  • 10.6 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Sales Channel
  • 10.7 Japan NASH Treatment & Therapeutics Market Analysis
  • 10.8 China NASH Treatment & Therapeutics Market Analysis
  • 10.9 India NASH Treatment & Therapeutics Market Analysis
  • 10.10 Australia NASH Treatment & Therapeutics Market (Pipeline Analysis) Analysis
  • 10.11 South Korea NASH Treatment & Therapeutics Market Analysis
  • 10.12 Singapore NASH Treatment & Therapeutics Market Analysis
  • 10.13 Rest of Asia Pacific NASH Treatment & Therapeutics Market Analysis

11 Latin America NASH Treatment & Therapeutics Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • 11.3 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) by Country, 2023, 2028 & 2033 (US$ Million)
  • 11.4 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Country
  • 11.5 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Application
  • 11.6 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Sales Channel
  • 11.7 Brazil NASH Treatment & Therapeutics Market Analysis
  • 11.8 Mexico NASH Treatment & Therapeutics Market Analysis
  • 11.9 Argentina NASH Treatment & Therapeutics Market Analysis
  • 11.10 Colombia NASH Treatment & Therapeutics Market Analysis
  • 11.11 Rest of Latin America NASH Treatment & Therapeutics Market Analysis

12 Middle East and Africa NASH Treatment & Therapeutics Market Analysis

  • 12.1 Key Findings
  • 12.2 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • 12.3 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) by Country, 2023, 2028 & 2033 (US$ Million)
  • 12.4 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Country
  • 12.5 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Application
  • 12.6 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Size Estimation and Forecast by Sales Channel
  • 12.7 GCC NASH Treatment & Therapeutics Market Analysis
  • 12.8 South Africa NASH Treatment & Therapeutics Market Analysis
  • 12.9 Rest of Middle East and Africa NASH Treatment & Therapeutics Market Analysis

13 Company Profiles

  • 13.1 Competitive Landscape, 2022
  • 13.2 Strategic Outlook
  • 13.3 Intercept Pharmaceuticals, Inc.
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2017-2022
      • 13.3.3.2 R&D, 2017-2022
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 Gilead Sciences Inc.
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 .Net Revenue, 2017-2022
      • 13.4.3.2 R&D, 2017-2022
      • 13.4.3.3 Regional Market Shares, 2022
    • 13.4.4 Product Benchmarking
  • 13.5 Genfit Pharma S.A.S
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2017-2022
      • 13.5.3.2 R&D, 2017-2022
    • 13.5.4 Product Benchmarking
  • 13.6 BioPredictive S.A.S
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Product Benchmarking
  • 13.7 Galmed Pharmaceuticals Ltd.
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Product Benchmarking
    • 13.7.4 Strategic Outlook
  • 13.8 Cadila Pharmaceuticals Ltd.
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Product Benchmarking
  • 13.9 Prometheus Laboratories Inc.
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Product Benchmarking
  • 13.10 AbbVie Inc.
    • 13.10.1 Company Snapshot
    • 13.10.2 Company Overview
    • 13.10.3 Financial Analysis
      • 13.10.3.1 Net Revenue, 2017-2022
      • 13.10.3.2 R&D, 2017-2022
      • 13.10.3.3 Regional Market Shares, 2022
    • 13.10.4 Product Benchmarking
    • 13.10.5 Strategic Outlook
  • 13.11 Enanta Pharmaceuticals Inc.
    • 13.11.1 Company Snapshot
    • 13.11.2 Company Overview
    • 13.11.3 Financial Analysis
      • 13.11.3.1 Net Revenue, 2017-2022
    • 13.11.4 Product Benchmarking
  • 13.12 Genentech, Inc.
    • 13.12.1 Company Snapshot
    • 13.12.2 Company Overview
    • 13.12.3 Product Benchmarking

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from
  • 14.2 Recommendations for Market Players

List of Tables

  • Table 1 NASH Treatment & Therapeutics Market (Pipeline Analysis) Snapshot, 2023 & 2033 (US$ Million, CAGR %)
  • Table 2 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
  • Table 5 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 6 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Product Type, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 7 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 8 Treatment Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 9 Diagnosis Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 10 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 11 Hospital Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 12 Online Provider Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 13 Retail Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 14 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 15 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Region, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 16 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 17 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 18 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 19 U.S. NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 20 Canada NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 21 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 22 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 23 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 24 Germany NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 25 France NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 26 UK NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 27 Italy NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 28 Spain NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 29 Russia NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 30 Rest of Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 31 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 32 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 33 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 34 Japan NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 35 China NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 36 India NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 37 Australia NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 38 South Korea NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 39 Singapore NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 40 Rest of Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 41 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 42 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 43 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 44 Brazil NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 45 Mexico NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 46 Argentina NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 47 Colombia NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 48 Rest of Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 49 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 50 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 51 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 52 GCC NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 53 South Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 54 Rest of Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR%, CAGR%)
  • Table 55 Strategic Outlook
  • Table 56 Intercept Pharmaceuticals, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 57 Intercept Pharmaceuticals, Inc.: Product Benchmarking
  • Table 58 Intercept Pharmaceuticals, Inc.: Strategic Outlook
  • Table 59 Gilead Sciences Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 60 Gilead Sciences Inc.: Product Benchmarking
  • Table 61 Genfit Pharma S.A.S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 62 Genfit Pharma S.A.S: Product Benchmarking
  • Table 63 BioPredictive S.A.S: Key Details, (HQ, Company Type, Website, Business Segment)
  • Table 64 BioPredictive S.A.S: Product Benchmarking
  • Table 65 Galmed Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Founded, Company Type, Website, Business Segment)
  • Table 66 Galmed Pharmaceuticals Ltd.: Product Benchmarking
  • Table 67 Galmed Pharmaceuticals Ltd.: Strategic Outlook
  • Table 68 Cadila Pharmaceuticals Ltd.: Key Details, (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 69 Cadila Pharmaceuticals Ltd.: Product Benchmarking
  • Table 70 Prometheus Laboratories Inc.: Key Details, (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 71 Prometheus Laboratories Inc.: Product Benchmarking
  • Table 72 AbbVie Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 73 AbbVie Inc.: Product Benchmarking
  • Table 74 AbbVie Inc.: Strategic Outlook
  • Table 75 Enanta Pharmaceuticals Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 76 Enanta Pharmaceuticals Inc.: Product Benchmarking
  • Table 77 Genentech, Inc.: Key Details, (CEO, HQ, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 78 Genentech, Inc.: Product Benchmarking
  •  

List of Figures

  • Figure 1 NASH Treatment & Therapeutics Market (Pipeline Analysis) Segmentation
  • Figure 2 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Application: Market Attractiveness Index
  • Figure 3 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Sales Channel: Market Attractiveness Index
  • Figure 4 NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index by Region
  • Figure 5 NASH Treatment & Therapeutics Market (Pipeline Analysis): Market Dynamics
  • Figure 6 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023-2033 (US$ Million, AGR %): "V" Shaped Recovery
  • Figure 7 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023-2033 (US$ Million, AGR %): "U" Shaped Recovery
  • Figure 8 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023-2033 (US$ Million, AGR %): "W" Shaped Recovery
  • Figure 9 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023-2033 (US$ Million, AGR %): "L" Shaped Recovery
  • Figure 10 NASH Treatment & Therapeutics Market (Pipeline Analysis): Porter's Five Forces Analysis
  • Figure 11 NASH Treatment & Therapeutics Market (Pipeline Analysis): PEST Analysis
  • Figure 12 NASH Treatment & Therapeutics Market (Pipeline Analysis): Drug Pipeline Analysis
  • Figure 13 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Product Type, 2023-2033 (US$ Million, AGR %)
  • Figure 14 NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Product Type, 2023, 2028, 2033 (%)
  • Figure 15 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Application: Market Attractiveness Index
  • Figure 16 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 17 NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Application, 2023, 2028, 2033 (%)
  • Figure 18 Treatment Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 19 Treatment Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 20 Diagnosis Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 21 Diagnosis Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 22 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Sales Channel: Market Attractiveness Index
  • Figure 23 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR %)
  • Figure 24 NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Sales Channel, 2023, 2028, 2033 (%)
  • Figure 25 Hospital Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 26 Hospital Pharmacy Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 27 Online Provider Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 28 Online Provider Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 29 Retail Pharmacy Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 30 Retail Pharmacy Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 31 Others Segment Market Forecast by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 32 Others Segment Market Share Forecast by Region, 2023 & 2033 (%)
  • Figure 33 NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Region 2023 and 2033 (Revenue, CAGR%)
  • Figure 34 NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Region 2023, 2028, 2033 (%)
  • Figure 35 NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023-2033 (US$ Million, AGR %)
  • Figure 36 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • Figure 37 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 38 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 39 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Country, 2023 & 2033 (%)
  • Figure 40 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 41 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Application, 2023 & 2033 (%)
  • Figure 42 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR %)
  • Figure 43 North America NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Sales Channel, 2023 & 2033 (%)
  • Figure 44 U.S. NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 45 Canada NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 46 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • Figure 47 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 48 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 49 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Country, 2023 & 2033 (%)
  • Figure 50 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 51 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Application, 2023 & 2033 (%)
  • Figure 52 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR %)
  • Figure 53 Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Sales Channel, 2023 & 2033 (%)
  • Figure 54 Germany NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 55 France NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 56 UK NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 57 Italy NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 58 Spain NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 59 Russia NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 60 Rest of Europe NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 61 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • Figure 62 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 63 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 64 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Country, 2023 & 2033 (%)
  • Figure 65 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 66 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Application, 2023 & 2033 (%)
  • Figure 67 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR %)
  • Figure 68 Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Sales Channel, 2023 & 2033 (%)
  • Figure 69 Japan NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 70 China NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 71 India NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 72 Australia NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 73 South Korea NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 74 Singapore NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 75 Rest of Asia Pacific NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 76 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • Figure 77 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 78 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 79 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Country, 2023 & 2033 (%)
  • Figure 80 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 81 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Application, 2023 & 2033 (%)
  • Figure 82 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR %)
  • Figure 83 Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Sales Channel, 2023 & 2033 (%)
  • Figure 84 Brazil NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 85 Mexico NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 86 Argentina NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 87 Colombia NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 88 Rest of Latin America NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 89 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Attractiveness Index
  • Figure 90 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) by Region, 2023, 2028 & 2033 (US$ Million)
  • Figure 91 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Country, 2023-2033 (US$ Million, AGR %)
  • Figure 92 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Country, 2023 & 2033 (%)
  • Figure 93 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Application, 2023-2033 (US$ Million, AGR %)
  • Figure 94 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Application, 2023 & 2033 (%)
  • Figure 95 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast by Sales Channel, 2023-2033 (US$ Million, AGR %)
  • Figure 96 Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Share Forecast by Sales Channel, 2023 & 2033 (%)
  • Figure 97 GCC NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 98 South Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 99 Rest of Middle East and Africa NASH Treatment & Therapeutics Market (Pipeline Analysis) Forecast, 2023-2033 (US$ Million, AGR %)
  • Figure 100 NASH Treatment & Therapeutics Market (Pipeline Analysis): Company Share/Ranking, 2022
  • Figure 101 Intercept Pharmaceuticals, Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 102 Intercept Pharmaceuticals, Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 103 Gilead Sciences Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 104 Gilead Sciences Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 105 Gilead Sciences Inc.: Regional Market Shares, 2022
  • Figure 106 Genfit Pharma S.A.S: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 107 Genfit Pharma S.A.S: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 108 AbbVie Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
  • Figure 109 AbbVie Inc.: R&D, 2017-2022 (US$ Million, AGR%)
  • Figure 110 AbbVie Inc.: Regional Market Shares, 2022
  • Figure 111 Enanta Pharmaceuticals Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)